Status:
RECRUITING
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
Lead Sponsor:
Vanderbilt University Medical Center
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
15+ years
Brief Summary
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators tre...
Detailed Description
This study will address the hypothesis that re-phenotyping patients with AF and pathogenic arrhythmia/CM variants will identify unrecognized underlying genetic disease. The investigators will recruit...
Eligibility Criteria
Inclusion
- Minors \>15 years
- Adult \> 18 years
- Able to provide written informed consent
- Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669)
- Atrial Fibrillation Ablation Registry (IRB#110881)
- Early-onset Atrial Fibrillation Registry (IRB#201666)
- Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene).
- Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65)
Exclusion
- Pregnant women
Key Trial Info
Start Date :
April 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT05190679
Start Date
April 27 2022
End Date
October 1 2026
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232